{
    "clinical_study": {
        "@rank": "97424", 
        "biospec_descr": {
            "textblock": "Whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "On a previous study conducted in Brazil.  The MMR vaccine from 2 different producers had a\n      mumps seroconversion much lower (71%) than the expected 95%, according to the package\n      insert. This could indicate that a substantial proportion of children was not protected\n      after MMR dose."
        }, 
        "brief_title": "Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)", 
        "completion_date": {
            "#text": "August 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Mumps", 
            "Rubella", 
            "Measles"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Measles", 
                "Mumps", 
                "Parotitis", 
                "Rubella"
            ]
        }, 
        "detailed_description": {
            "textblock": "Given the above and considering: (1) future clinical study with the MMR vaccine produced\n      entirely in Bio-Manguinhos/Fiocruz from technology transfer from GlaxoSmithKline (GSK), (2)\n      the importance to the National Immunization Program (NIP) to provide the population a MMR\n      vaccine to ensure high protection against mumps, similar to what occurs with measles and\n      rubella components, it was considered essential to conduct a preliminary immunogenicity\n      assessment of the MMR vaccine produced by BioManguinhos."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children of both sexes;\n\n          -  Age between 12 months to 23 months and 29 days;\n\n          -  Child in good health, with no significant past medical history;\n\n          -  Have completed blood sampling before vaccination;\n\n          -  Have not been vaccinated with MMR.\n\n          -  Agreement by parents/tutors with the child's participation in the study and signing\n             of the Informed Consent Form (ICF);\n\n          -  Parents/Tutors provide name, address, telephone number and other information  for the\n             contact if necessary;\n\n          -  Parents/Tutors able to understand the risks of the experiment, although minimal;\n\n          -  Parents/Tutors able to understand and sign the informed consent form.\n\n          -  Availability of return for collecting post-vaccination samples.\n\n        Exclusion criteria:\n\n          -  Children with a history of measles, rubella and / or mumps.\n\n          -  Having received MMR vaccine previously, as documented in vaccination card.\n\n          -  Having received a transfusion of blood or blood products, including immunoglobulins,\n             within last 12 months.\n\n          -  Skin lesions at sites of venipuncture.\n\n          -  Child subject to abnormal bleeding after injections.\n\n          -  Use within 6 months of corticosteroids (excluding topical or aerosol) and\n             immunosuppressants."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "24 Months", 
            "minimum_age": "12 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Children 12-23 months and 29 days old, in the routine of PNI in health units in the city\n        of Rio de Janeiro."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874457", 
            "org_study_id": "ASCLIN/002/2008"
        }, 
        "intervention": {
            "description": "MMR (Mumps, Measles and Rubella)", 
            "intervention_name": "MMR (Mumps, Measles and Rubella)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rio de Janeiro", 
                    "country": "Brazil", 
                    "zip": "21040-360"
                }, 
                "name": "Bio-Manguinhos/Fiocruz"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Serological Study of Measles, Mumps and Rubella in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) in Health Centers Where a Phase III Study Should be Conducted", 
        "overall_official": {
            "affiliation": "Immunobiological Technology Institute (Bio-Manguinhos)", 
            "last_name": "Gl\u00f3ria Regina da Silva e S\u00e1, Doctorate", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Brazil: National Agency for Sanitary Vigilance (ANVISA)", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assess the immunoresponse for measles, mumps and rubella after vaccination with MMR in children 12-23 months and 29 days old, in the routine of National Immunization Program (NIP) in health units in the city of Rio de Janeiro.", 
            "measure": "Immunoresponse after first dose", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874457"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the immunoresponse after revaccination of children who did not seroconvert for any of the three components of the vaccine.", 
            "measure": "Immunoresponse after revaccination", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "source": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2008", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}